Is arqt will up tomorrow?

Arcutis Biotherapeutics (ARQT) is likely to face upward pressure in the short term, based on several factors:

1. Positive Analyst Ratings and Price Targets: The consensus rating for ARQT is a "Strong Buy" with an average price target of $17.33. This suggests that analysts are optimistic about the stock's future performance.

2. Technical Indicators: Although specific technical indicators such as MACD, RSI, and KDJ are not available the absence of these indicators does not necessarily indicate a bearish or bullish trend. The lack of data for moving averages and support and resistance levels also implies that there is no clear technical trend to predict.

3. Financial Performance: The company's diluted EPS is -$0.32, and it has a negative net income of $35.38 million. These figures indicate that ARQT is currently unprofitable. However, the gross profit margin is exceptionally high at 214.72%, which could be due to the company's unique business model or one-time events.

4. Valuation Metrics: The P/E ratio is -4.95, the P/S ratio is 12.47, and the Price to Book Ratio is 4.73. These figures indicate that the stock may be undervalued relative to its earnings and book value, which could attract investors looking for value stocks.

5. Market Performance and Zacks Rank: ARQT has outperformed its peers in the Medical sector and has a Zacks Rank of #2 (Buy). This suggests that the stock has strong fundamentals and a positive short-term outlook.

6. Recent Company Developments: Arcutis has announced positive developments, such as the acceptance of abstracts at a dermatology conference, which could contribute to investor confidence and potential stock price appreciation.

In conclusion, while the lack of specific technical indicators and financials makes it difficult to provide a definitive prediction, the overall sentiment from analysts and the company's recent performance suggest that ARQT could experience an upward trend in the near future. However, investors should also consider their own risk tolerance and investment strategy before making any decisions.